REAP Financial Group’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$518K Sell
448
-54
-11% -$63.7K 0.08% 73
2026
Q2
$603K Sell
502
-2
-0.4% -$2.04K 0.1% 67
2026
Q1
$463K Buy
504
+8
+2% +$8.11K 0.09% 74
2025
Q4
$533K Buy
496
+261
+111% +$250K 0.11% 68
2025
Q3
$179K Sell
235
-12
-5% -$8.93K 0.04% 121
2025
Q2
$192K Buy
247
+107
+76% +$83.1K 0.05% 117
2025
Q1
$115K Buy
140
+31
+28% +$25.8K 0.03% 141
2024
Q4
$84.4K Sell
109
-36
-25% -$29.8K 0.02% 172
2024
Q3
$128K Buy
145
+98
+209% +$88.1K 0.03% 141
2024
Q2
$42.3K Buy
47
+1
+2% +$800 0.01% 202
2024
Q1
$35.5K Buy
46
+5
+12% +$3.56K 0.01% 226
2023
Q4
$23.7K Buy
+41
New +$23.9K 0.01% 317

Other funds holding LLY

REAP Financial Group's LLY Position: Q3 2026 in Review

REAP Financial Group reduced its Eli Lilly (LLY) stake by 11% in Q3 2026, selling an estimated $63.7K and leaving 448 shares worth $518K. The position accounts for 0.08% of the portfolio, ranked #73.

REAP Financial Group first reported a position in LLY in Q4 2023 and has held it in 12 quarters since. The position peaked at $603K in Q2 2026. 4,625 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • REAP Financial Group held 448 shares of Eli Lilly worth $518K as of Q3 2026.
  • REAP Financial Group sold 54 Eli Lilly shares in Q3 2026, an estimated $63.7K.
  • Eli Lilly made up 0.08% of REAP Financial Group's portfolio in Q3 2026, its #73 holding.
  • REAP Financial Group first reported a position in Eli Lilly in Q4 2023 and has held it in 12 quarters since.
  • REAP Financial Group's Eli Lilly position peaked at $603K in Q2 2026.
  • 4,625 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on REAP Financial Group's 13F filing for Q3 2026, filed 2 Nov 2026.